drugset / Trial / NCT00174382

Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

NCT00174382

Phase 3 Terminated 149 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.

Timeline

Start
2005-06
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg
Subject Donepezil Small molecule 10 mg

Indications